pharmaceuticals

FAS addressed medical institutions
FAS asked medical institutions to submit information about the issue related to absence of approved licensing requirements
more
FAS opened a case against “Novartis Pharma” Ltd.
The company is suspected of fixing monopolistically high price for “Tyverb” medicinal drug
more
FAS exposed excessive prices for preventive-and-immune drug
The third stage of comparative analysis of drug prices exposed pricing violations for 7 medicines in Russia
more
FAS managed to decrease 239 prices on the drugs for treating HIV, tuberculosis, hepatitis B and C
The minimum saving of budgetary funds from reducing prices will reach over 63 million RUB for the Ministry of health Care for HIV-treatment drugs
more